Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Integrin βL1 Inhibitors

Integrin βL1 inhibitors are a chemical class designed to interfere with the function of Integrin βL1, a protein that plays a crucial role in cell adhesion, migration, and signal transduction. These inhibitors encompass a range of small molecules and peptides that can bind to the active site or allosteric sites of Integrin βL1, blocking its interaction with extracellular matrix proteins or counter-receptors on adjacent cells. The inhibitors can operate by mimicking the natural ligands of the integrin, effectively competing for the binding sites and preventing the integrin from engaging with its partners. Some inhibitors act as antagonists by fitting into the binding groove of Integrin βL1, where they can obstruct the normal ligand-receptor interactions without triggering the conformational changes required for signal transduction.

Moreover, this class includes molecules that can influence Integrin βL1 signal transduction pathways. By targeting key enzymes and kinases involved in the downstream signaling of Integrin βL1, these inhibitors can alter the intracellular response typically initiated by integrin-ligand binding. For instance, some inhibitors focus on the focal adhesion kinase (FAK) or the Src family kinases, both of which are pivotal in relaying signals from Integrin βL1 to the cell's interior. Inhibition of these kinases can disrupt the cascade of events that lead to cellular responses to integrin engagement. Additionally, other inhibitors can alter the cytoskeletal dynamics that are essential for the integrin-mediated cell adhesion and movement by disrupting actin polymerization or myosin light chain kinase activity. The diverse mechanisms of action within this class of inhibitors underscore the complexity of Integrin βL1's role in cellular processes and the sophisticated approaches required to modulate its activity. Each inhibitor is characterized by its unique interaction with Integrin βL1 or its signaling pathways, providing a toolbox of molecular entities that can modulate the integrin's function in various ways.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tirofiban-d6

144494-65-5 (unlabeled)sc-475655
1 mg
$450.00
(0)

Tirofiban is a non-peptide antagonist that inhibits Integrin βL1 by blocking the fibrinogen binding site, thus preventing platelet aggregation and thrombus formation.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$94.00
$227.00
30
(1)

PP2 is a Src family kinase inhibitor that could possibly inhibit Integrin βL1 through the prevention of Src kinase activity, which is involved in Integrin βL1-mediated signal transduction.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor that could possibly inhibit Integrin βL1 by blocking the PI3K/Akt pathway, downstream of Integrin βL1 engagement.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a multi-target tyrosine kinase inhibitor that could possibly inhibit Integrin βL1-related pathways by targeting Src family kinases and other kinases involved in Integrin βL1 signaling.

Cytochalasin D

22144-77-0sc-201442
sc-201442A
1 mg
5 mg
$165.00
$486.00
64
(4)

Cytochalasin D disrupts actin polymerization, which could possibly impair Integrin βL1-mediated cell attachment and migration by altering the cytoskeleton.

Fibronectin

sc-29011
sc-29011A
1 mg
5 mg
$143.00
$504.00
94
(3)

RGDS Peptide is a synthetic peptide that contains the RGD sequence, inhibiting Integrin βL1 by blocking the binding sites for ECM proteins.

ML-7 hydrochloride

110448-33-4sc-200557
sc-200557A
10 mg
50 mg
$91.00
$267.00
13
(1)

ML7 is a myosin light chain kinase inhibitor that could possibly inhibit Integrin βL1 by affecting cell contractility and migration, processes in which Integrin βL1 is involved.